Adalimumab (Humira) is the most expensive drug in the world in terms of total sales: $19.9 billion in 2018. Five biosimilars (generic equivalents) have been approved by the FDA, but none have been marketed because they have been locked up in patent disputes by the manufacturer, Abbvie. The story is much...
Read More »